Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

Novartis

Status: Completed

Conditions: HIV Infections; Candidiasis, Oral

Treatments: Drug: Terbinafine hydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002394

SFS 257-E-00

282A

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.

Full description

This is an open-label, dose-escalating study with up to 2 sequential cohorts. The first 15 patients receive Lamisil for 2 weeks. After 2 weeks, patients considered clinically cured (i.e., absence of removable, white plaques) are removed from treatment; patients not considered clinically cured receive an additional 2 weeks of treatment. At the end of 4 weeks, treatment is discontinued, regardless of clinical cure outcome. If less than 80% of patients are clinically cured after the 4 weeks of treatment, a second cohort of 15 patients receive Lamisil on the same treatment regimen as first cohort (i.e., initial 2-week treatment period, with an additional 2 weeks of treatment for those patients who are not considered clinically cured after 2 weeks of treatment).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are at least 18 years old.
• Have thrush that has not responded to at least 10 days of fluconazole treatment.
• Are HIV-positive.
• Are expected to live at least 4 weeks.
• Are able to take oral medication.

Exclusion Criteria

You will not be eligible for this study if you:

• Have liver or kidney disease.
• Have received certain medications.
• Have a history of serious diarrhea or digestive problems.
• Are pregnant or breast-feeding.